Temporal Dynamic of Efficacy and Tolerability of Artemether–Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Bouna, Côte d’Ivoire
1 Département de Parasitologie, Mycologie, Biologie Animale et Zoologie, Université Felix Houphouët Boigny, Abidjan BPV 34, Côte d’Ivoire; (V.A.B.-T.); (F.K.K.); (E.M.K.); (H.V.-B.); (E.K.A.); (J.S.A.M.); (V.D.); (C.P.K.-B.); (H.E.M.); (W.Y.)
2 Centre de Recherche et de Lutte Contre le Paludisme, Institut National de Santé Publique, Abidjan BPV 47, Côte d’Ivoire;
3 Projet de Recherches Cliniques sur la Trypanosomiase, Institut National de Santé Publique, Abidjan BPV 47, Côte d’Ivoire;
4 Laboratoire de Parasitologie et de Mycologie, Centre de Diagnostic et de Recherche sur le SIDA et les Autres Maladies Infectieuses, Centre Hospitalier Universitaire de Treichville, Abidjan BPV 13, Côte d’Ivoire
5 Département de Paludologie, Institut Pasteur de Côte d’Ivoire, Boulevard Université, Abidjan 01 BP 490 Abidjan 01, Côte d’Ivoire;
* Author to whom correspondence should be addressed.
Received: 19 Jun 2025 / Accepted: 31 Mar 2026 / Published: 15 Apr 2026
Abstract
Introduction: Therapeutic Efficacy Studies (TESs) are crucial for detecting early changes in P. falciparum susceptibility to antimalarial drugs. Artemether–lumefantrine is one of five first-line treatments for uncomplicated malaria in Côte d’Ivoire. This study aimed to assess the temporal dynamics of artemether–lumefantrine (AL) efficacy in managing uncomplicated malaria cases in Bouna, a sentinel site. Methods: This was a comparative analysis of two controlled, randomized, and open therapeutic trials based on a 28-day follow-up period, conducted according to the 2009 WHO protocol. The surveys were conducted in 2019 and 2023. Treatment response was measured and defined following WHO guidelines, with analyses performed using intention-to-treat and per-protocol methods. Results: A 28-day follow-up was performed for 57 and 87 patients in 2019 and 2023, respectively. On day 28, the PCR-adjusted cure rates were higher in 2023 than in 2019, both in ITT analysis (96.6% versus 90.0%) and in PP analysis (97.7% versus 94.7%). However, more failures were observed after 28 days of follow-up in 2023 (23 cases) than in 2019 (9 cases). After PCR adjustment, nearly all cases were attributed to reinfection. In 2019, three cases of recurrence and six new infections were observed. In 2023, two recurrence events and 21 new infections were observed. In both surveys, AL was well-tolerated. Conclusions: This comparative assessment demonstrated that AL remains effective in treating uncomplicated malaria in Bouna. The high number of new infections highlights the need to strengthen preventive measures.
Keywords: malaria; efficacy; artemether–lumefantrine; Côte d’Ivoire
OPEN ACCESS
This is an open access article distributed under the Creative Commons Attribution
License which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. (CC BY 4.0).
CITE
Konaté-Touré, A.; Dablé, M.T.; Bédia-Tanoh, V.A.; Gnagne, P.A.; Kassi, F.K.; Koné, E.M.; Vanga-Bosson, H.; Angora, E.K.; Miezan, J.S.A.; Djohan, V.; Kiki-Barro, C.P.; Touré, O.A.; Menan, H.E.; Yavo, W. Temporal Dynamic of Efficacy and Tolerability of Artemether–Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Bouna, Côte d’Ivoire. AJPME 2026, 3, 11.
Konaté-Touré A, Dablé MT, Bédia-Tanoh VA, Gnagne PA, Kassi FK, Koné EM, Vanga-Bosson H, Angora EK, Miezan JSA, Djohan V, Kiki-Barro CP, Touré OA, Menan HE, Yavo W. Temporal Dynamic of Efficacy and Tolerability of Artemether–Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Bouna, Côte d’Ivoire. AJPME. 2026; 3(2):11.
Konaté-Touré, Abibatou; Dablé, Marius T.; Bédia-Tanoh, Valérie A.; Gnagne, Paterne A.; Kassi, Fulgence K.; Koné, Estelle MG; Vanga-Bosson, Henriette; Angora, Etienne K.; Miezan, Jean Sebastien A.; Djohan, Vincent; Kiki-Barro, Christiane P.; Touré, Offianan A.; Menan, Hervé EI; Yavo, William. 2026. "Temporal Dynamic of Efficacy and Tolerability of Artemether–Lumefantrine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Bouna, Côte d’Ivoire." AJPME 3, no. 2: 11.
Not implemented
SHARE
